Author:
Beitelshees Amber L.,McLeod Howard L.
Reference42 articles.
1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research (2005) Good pharmacovigilance practices and pharmacoepidemiologic assessment (http://www.fda.gov/cder/guidance/6359OCC.htm)
2. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women;Ridker;N. Engl. J. Med.,2000
3. C-reactive protein levels and outcomes after statin therapy;Ridker;N. Engl. J. Med.,2005
4. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men;Ridker;N. Engl. J. Med.,1997
5. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease;Campbell;Circulation,2005
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献